Insulet (NSDQ:PODD) today said it has resumed its pivotal study of its next-generation Omnipod Insulin Management System after pausing the study in March due to a software anomaly.
The company paused the study about halfway through completion to correct an issue that could result in the system using an incorrect glucose value that had the potential to impact insulin delivery, according to the company. No adverse events it had been reported due to the software issue.
